MWNA
CALT

Marshall Wace North America’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

Marshall Wace North America’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,535
Closed -$432K – 1534
2020
Q2 		$432K Buy
+18,535
New +$367K ﹤0.01% 949

Other funds holding CALT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Marshall Wace North America's CALT Position: Q3 2020 in Review

Marshall Wace North America sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2020, closing a stake of 18,535 shares — an estimated $432K sold.

Marshall Wace North America first reported a position in CALT in Q2 2020 and held it in 1 quarter. The position peaked at $432K in Q2 2020. 16 funds tracked by Wall St. Rank hold CALT as of Q3 2020.

  • Marshall Wace North America reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2020 after selling out during the quarter.
  • Marshall Wace North America sold 18,535 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2020, an estimated $432K.
  • Marshall Wace North America first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2020 and held it in 1 quarter.
  • Marshall Wace North America's Calliditas Therapeutics AB American Depositary Shares position peaked at $432K in Q2 2020.
  • 16 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2020.

Based on Marshall Wace North America's 13F filing for Q3 2020, filed 16 Nov 2020.